Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Bone metastasis in breast carcinoma]

O Kölbl1, I C Kiricuta, J Willner

  • 1Klinik und Poliklinik für Strahlentherapie, Universität Würzburg.

Zentralblatt Fur Chirurgie
|January 1, 1997
PubMed
Summary

Metastatic breast cancer frequently affects the skeletal axis, with skeletal metastases often being the first sign of disease progression. Despite a median survival of 1.7 years, combined therapies may improve outcomes for these patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Interobserver agreement on definition of the target volume in stereotactic radiotherapy for pancreatic adenocarcinoma using different imaging modalities.

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]·2023
Same author

Metal-containing landfills as a source of antibiotic tolerance.

Environmental monitoring and assessment·2023
Same author

Integration of radiation oncology teaching in medical studies by German medical faculties due to the new licensing regulations : An overview and recommendations of the consortium academic radiation oncology of the German Society for Radiation Oncology (DEGRO).

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]·2021
Same author

Change of collective orientation through an interprofessional training with medical students and student nurses depending on presence and professional group.

BMC medical education·2021
Same author

Improving interinstitutional and intertechnology consistency of pulmonary SBRT by dose prescription to the mean internal target volume dose.

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]·2021
Same author

Induction chemotherapy (IC) followed by radiotherapy (RT) versus cetuximab plus IC and RT in advanced laryngeal/hypopharyngeal cancer resectable only by total laryngectomy-final results of the larynx organ preservation trial DeLOS-II.

Annals of oncology : official journal of the European Society for Medical Oncology·2018

Area of Science:

  • Oncology
  • Radiotherapy
  • Medical Statistics

Context:

  • Retrospective analysis of 278 metastatic breast cancer patients treated between 1978 and 1988.
  • Focus on the incidence and characteristics of skeletal metastases.
  • Investigated skeletal metastases as the initial presentation of metastatic breast cancer.

Purpose:

  • To analyze the occurrence and impact of skeletal metastases in metastatic breast cancer patients.
  • To determine the median age, interval to skeletal metastasis, and survival rates.
  • To evaluate the influence of skeletal metastases on overall survival in the context of other existing metastases.

Summary:

  • 192 out of 278 patients developed skeletal metastases, predominantly affecting the skeletal axis.
  • Skeletal metastasis was the first sign of disease in 58.3% of patients.

Related Experiment Videos

  • Median age at diagnosis of skeletal metastasis was 62.5 years, with a median interval of 2.9 years from primary diagnosis. Median survival was 1.7 years, but did not worsen survival if other metastases were present.

    • Impact:

    • Highlights the significant prevalence of skeletal metastases in advanced breast cancer.
    • Suggests a relatively good prognosis for skeletal metastases, especially when not accompanied by other metastatic sites.
    • Emphasizes the need for improved and combined local and systemic therapeutic strategies for managing skeletal metastases in breast cancer.